The global intelligence OS for pain medicine –
connecting 25+ countries through one unified platform
PIN is not a registry. It is a data-powered, physician-governed operating system for the world's most underserved chronic disease · enhanced with a pharmacovigilance layer that makes it the only real-world platform where clinical outcomes and drug safety data live in the same longitudinal dataset. Regulators, payers, and pharma sponsors have been waiting for this for decades.
| Revenue Stream | Model | Yr 1 | Yr 2 | Yr 3 | Status |
|---|---|---|---|---|---|
Industry Sponsorships Pharma/medtech KOL + data access | Annual contract | $150K | $500K | $1.2M | Live |
PASS / PMS Study Fees Post-authorization safety studies | $50K–$150K/study | $85K | $400K | $1.6M | Growing |
PV Signal Detection SaaS Pharma PV teams · annual signal license | $80K–$200K/yr | – | $240K | $1.4M | Phase 2 |
Opioid Risk AI Licensing API to payers / hospital systems | SaaS + API | – | $200K | $1.8M | Phase 2 |
Institutional VBP Subscriptions Hospital LPTM + benchmarking | $10K–$50K/site/yr | $60K | $400K | $2.1M | Pilot |
Research Registry Access De-identified data for academia/industry | Per-study fee | $80K | $350K | $1.5M | Live |
Premium Memberships + CME $200–$300/yr individual | Individual SaaS | $80K | $220K | $600K | Live |
- 5 pilot sites · 500 patients
- 5 AI modules live
- PV signal detection pilot with 1 pharma partner
- First PASS study contract signed ($85K)
- STAR/HEDIS reporting live for 2 payer plans
- 20+ sites · 3,000 patients · 12 countries
- 3 active PASS studies · 2 pharma PV clients
- PV SaaS launched · PSUR auto-generation
- ARR: $370K → $1.6M
- Partnerships with 15+ global pain organizations
- 100+ sites · 15,000+ patients · 25+ countries
- Full PV platform · 8+ pharma clients
- Government / EMA / FDA / Health Canada contracts
- Opioid Risk AI licensed to 10+ global payers
- ARR → $10M+
Pain Medicine is at an Inflection Point
The convergence of regulatory mandates (FDA Sentinel, EMA PASS), value-based care contracts, and AI-readiness has created a $600M addressable market for intelligence platforms that can bridge clinical practice, research, and pharmacovigilance.
- → FDA Sentinel Initiative mandates real-world evidence for drug safety
- → EMA PASS studies now required for all new pain therapeutics
- → Value-based contracts require STAR/HEDIS quality reporting
- → Multi-site trials demand unified data standards (CDISC/OMOP)
First-Mover Advantage
PIN is the only platform designed specifically for pain medicine with built-in pharmacovigilance, multi-site research capabilities, and payer analytics in a single integrated OS.
Join the Global Intelligence Revolution in Pain Medicine
PIN is positioned to become the standard global data infrastructure for pain medicine—connecting 25+ countries, 130+ clinical sites, and pharmaceutical safety surveillance in a single, unified platform. The window for early participation is closing.
For investor inquiries, contact:
investors@paininnovation.network